Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vittorio Di Maso

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Kidney International Reports|October 27, 2025
Is Monotherapy Enough? Rethinking Strategies for Active Lupus Nephritis Network Meta-Analysis of Active Lupus Nephritis TreatmentVittorio Di Maso, Giacomo Emmi
F1000 Medicine Reports|October 16, 2010
Is there an effective therapy available for non-alcoholic fatty liver disease?Vittorio Di Maso, Stefano Bellentani
International Journal of Molecular Sciences|November 21, 2014
Small molecule membrane transporters in the mammalian podocyte: a pathogenic and therapeutic targetCristina Zennaro, Mary Artero, Vittorio Di Maso, et al.
Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia|October 20, 2021
[Droghe d'abuso e rene]Giuliano Boscutti, Vittorio Di Maso, Alessandra Marega, et al.
Journal of Chemotherapy (Florence, Italy)|August 21, 2023
Vancomycin-resistant enterococcus bloodstream infection successfully managed with oritavancin and fosfomycin as sequential treatmentCaterina Di Cecco, Jacopo Monticelli, Stefano Di Bella, et al.
Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia|June 29, 2024
[COVID-19 and Lupus Nephritis Flares in Unvaccinated Patients: A Case Report and Literature Review]Brigitta Perencin, Alberto Zacchi, Fabrizio Zanconati, et al.
Pediatric Nephrology (Berlin, Germany)|July 26, 2023
Pioglitazone, a PPAR-y agonist, as one of the new therapeutic candidates for C3 glomerulopathyElia Balestra, Egidio Barbi, Viola Ceconi, et al.
Clinical Kidney Journal|April 11, 2015
Warfarin-related nephropathy: possible role for the warfarin pharmacogenetic profileVittorio Di Maso, Michele Carraro, Elena Bevilacqua, et al.
Current Cardiology Reports|February 4, 2026
Cardiorenal and Metabolic Dimensions of Cardiomyopathies and Heart Failure: Focus on SGLT2i, GLP1-RA, and ns-MRACarla Indennidate, Brigitta Perencin, Vittorio Di Maso, et al.
The International Journal of Artificial Organs|January 25, 2022
Effects of the timing and intensity of treatment on septic shock patients treated with CytoSorb<sup>®</sup>: Clinical experienceGiorgio Berlot, Valentina Samola, Ilaria Barbaresco, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Kidney International Reports|October 27, 2025
Is Monotherapy Enough? Rethinking Strategies for Active Lupus Nephritis Network Meta-Analysis of Active Lupus Nephritis TreatmentVittorio Di Maso, Giacomo Emmi
F1000 Medicine Reports|October 16, 2010
Is there an effective therapy available for non-alcoholic fatty liver disease?Vittorio Di Maso, Stefano Bellentani
International Journal of Molecular Sciences|November 21, 2014
Small molecule membrane transporters in the mammalian podocyte: a pathogenic and therapeutic targetCristina Zennaro, Mary Artero, Vittorio Di Maso, et al.
Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia|October 20, 2021
[Droghe d'abuso e rene]Giuliano Boscutti, Vittorio Di Maso, Alessandra Marega, et al.
Journal of Chemotherapy (Florence, Italy)|August 21, 2023
Vancomycin-resistant enterococcus bloodstream infection successfully managed with oritavancin and fosfomycin as sequential treatmentCaterina Di Cecco, Jacopo Monticelli, Stefano Di Bella, et al.
Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia|June 29, 2024
[COVID-19 and Lupus Nephritis Flares in Unvaccinated Patients: A Case Report and Literature Review]Brigitta Perencin, Alberto Zacchi, Fabrizio Zanconati, et al.
Pediatric Nephrology (Berlin, Germany)|July 26, 2023
Pioglitazone, a PPAR-y agonist, as one of the new therapeutic candidates for C3 glomerulopathyElia Balestra, Egidio Barbi, Viola Ceconi, et al.
Clinical Kidney Journal|April 11, 2015
Warfarin-related nephropathy: possible role for the warfarin pharmacogenetic profileVittorio Di Maso, Michele Carraro, Elena Bevilacqua, et al.
Current Cardiology Reports|February 4, 2026
Cardiorenal and Metabolic Dimensions of Cardiomyopathies and Heart Failure: Focus on SGLT2i, GLP1-RA, and ns-MRACarla Indennidate, Brigitta Perencin, Vittorio Di Maso, et al.
The International Journal of Artificial Organs|January 25, 2022
Effects of the timing and intensity of treatment on septic shock patients treated with CytoSorb<sup>®</sup>: Clinical experienceGiorgio Berlot, Valentina Samola, Ilaria Barbaresco, et al.
Pageof 3